Evidence map›Paper›PMID 27846155›Full record

ArticleTransplantation2017

Effect of Ex Vivo-Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques.

Raimon Duran-Struuck, Hugo P Sondermeijer, Leo Bühler, Paula Alonso-Guallart, Jonah Zitsman, Yojiro Kato, Anette Wu, Alicia N McMurchy, David Woodland, Adam Griesemer and 18 more

Erratum issuedAbstract read
In one paragraph

Article in Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Developments in kidney xenotransplantation.Frontiers in immunology · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Expansion of CD45RAClinical & translational immunology · 2021
    Article
  13. Apoptotic Donor Cells in Transplantation.Frontiers in immunology · 2021
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 4 countries.

Raimon Duran-Struuck *Columbia University Medical Center, New York, NY, United States.
Hugo P Sondermeijer *Columbia University Medical Center, New York, NY, United States.
Leo BühlerGeneva University Hospital, Geneva, Switzerland.
Paula Alonso-GuallartColumbia University Medical Center, New York, NY, United States.
Jonah ZitsmanColumbia University Medical Center, New York, NY, United States.
Yojiro KatoColumbia University Medical Center, New York, NY, United States.
Anette WuColumbia University Medical Center, New York, NY, United States.
Alicia N McMurchyUniversity of British Columbia, Vancouver, British Columbia, Canada.
David WoodlandColumbia University Medical Center, New York, NY, United States.
Adam GriesemerColumbia University Medical Center, New York, NY, United States.
Mercedes MartinezColumbia University Medical Center, New York, NY, United States.
Svetlan BoskovicMassachusetts General Hospital, Boston. MA, United States.
Tatsuo KawaiMassachusetts General Hospital, Boston. MA, United States.
A Benedict CosimiMassachusetts General Hospital, Boston. MA, United States.
Yong-Guang Yang
Zheng Hu
Cheng-Shie WuuColumbia University Medical Center, New York, NY, United States.
Andrea SlateColumbia University Medical Center, New York, NY, United States.
Markus MaparaColumbia University Medical Center, New York, NY, United States.
Sam BakerColumbia University Medical Center, New York, NY, United States.
Rafal TokarzColumbia University Medical Center, New York, NY, United States.
Vivette D'AgatiColumbia University Medical Center, New York, NY, United States.
Scott HammerColumbia University Medical Center, New York, NY, United States.
Marcus PereiraColumbia University Medical Center, New York, NY, United States.
W Ian LipkinColumbia University Medical Center, New York, NY, United States.
Thomas WekerleSection of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, Austria.
Megan LevingsUniversity of British Columbia, Vancouver, British Columbia, Canada.
Megan SykesColumbia University Medical Center, New York, NY, United States.
Columbia University Irving Medical Center · USMassachusetts General Hospital · USUniversity of British Columbia · CAMedical University of Vienna · ATUniversity Hospital of Geneva · CH

Funding

Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Robust allograft tolerance in non-human primatesR01OD017949 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SYKES, MEGAN · 2015 to 2019
$4.5M
BD Biosciences InfluxS10OD020056 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SNOECK, HANS-WILLEM E · 2015 to 2015
$600k
Becton Dickinson LSR II Analytical Flow CytometerS10RR027050 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLYNES, RAPHAEL A. · 2011 to 2011
$413k
NCRR NIH HHS S10 RR027050NIAID NIH HHS U24 AI126683NIH HHS R01 OD017949
6 · The paper itself

Abstract

backgroundInfusion of recipient regulatory T (Treg) cells promotes durable mixed hematopoietic chimerism and allograft tolerance in mice receiving allogeneic bone marrow transplant (BMT) with minimal conditioning. We applied this strategy in a Cynomolgus macaque model.

methodsCD4 CD25 Treg cells that were polyclonally expanded in culture were highly suppressive in vitro and maintained high expression of FoxP3. Eight monkeys underwent nonmyeloablative conditioning and major histocompatibility complex mismatched BMT with or without Treg cell infusion. Renal transplantation (from the same BMT donor) was performed 4 months post-BMT without immunosuppression to assess for robust donor-specific tolerance.

resultsTransient mixed chimerism, without significant T cell chimerism, was achieved in the animals that received BMT without Treg cells (N = 3). In contrast, 2 of 5 recipients of Treg cell BMT that were evaluable displayed chimerism in all lineages, including T cells, for up to 335 days post-BMT. Importantly, in the animal that survived long-term, greater than 90% of donor T cells were CD45RA CD31, suggesting they were new thymic emigrants. In this animal, the delayed (to 4 months) donor kidney graft was accepted more than 294 days without immunosuppression, whereas non-Treg cell BMT recipients rejected delayed donor kidneys within 3 to 4 weeks. Early CMV reactivation and treatment was associated with early failure of chimerism, regardless of Treg cell administration.

conclusionsOur studies provide proof-of-principle that, in the absence of early CMV reactivation (and BM-toxic antiviral therapy), cotransplantation of host Treg cell can promote prolonged and high levels of multilineage allogeneic chimerism and robust tolerance to the donor.

Indexed as

Graft SurvivalHistocompatibilityTransplantation ToleranceAllograftsAnimalsAntiviral AgentsBiomarkersBone Marrow TransplantationCell ProliferationCells, CulturedCytomegalovirus InfectionsGraft RejectionHistocompatibility AntigensKidney TransplantationMacaca fascicularisMaleAntiviral AgentsBiomarkersHistocompatibility Antigens

Identifiers

PMID27846155
PMCPMC5263090
OpenAlexW2557178154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.